Improved Transfection Efficiency Using Combination Lipoids (22112)
Robert C. MacDonald et al., developed novel liposomes useful as transfection agents to deliver nucleic acids to cells for which efficient transfection with conventional agents is difficult. The novel transfection agent, MLS, is a mixture of two cationic components (L and S) that are combined in different proportions to optimize the efficiency of DNA delivery. The significance of this agent is its markedly enhanced transfection efficiency when "tuned" to a given cell type and conditions. Transfection efficiency of the optimal combination can be 25-fold higher than for either of the components separately.
BACKGROUND: The efficiency of transfection using the lipoids of this invention were compared with Effectene® from Qiagen. Effectene, a commercially available product is marketed for the effective transfection of cells that are traditionally difficult to transfect, including smooth muscle cells, primary cell lines, and endothelial cells, among others. As illustrated below for expression in 96-well plates, the lipids of this invention are highly effective, and considerably better than Effectene at promoting transfection in human umbilical artery endothelial cells (HUAEC). The figure below also demonstrates that the composition may readily be optimized for different conditions, i.e., one composition is optimal in the absence of serum (8:2) and another is most effective in the presence of serum (6:4). Thus, these novel lipoids are highly effective and useful as cellular transfection reagents that can be used by laboratories to enhance transfection of difficult to transfect cultured cells. They also offer new possibilities for optimizing in vivo gene delivery.
Li Wang and Robert C. MacDonald
Type of Offer:
« More Life Sciences Patents